Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for MRKR.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 1999. Start Trial.
Date Value
June 30, 2026 12.17M
March 31, 2026 13.80M
December 31, 2025 16.80M
September 30, 2025 18.39M
June 30, 2025 10.49M
March 31, 2025 14.49M
December 31, 2024 18.56M
September 30, 2024 7.450M
June 30, 2024 9.703M
March 31, 2024 11.79M
December 31, 2023 14.05M
September 30, 2023 16.71M
June 30, 2023 19.03M
March 31, 2023 15.91M
December 31, 2022 19.60M
September 30, 2022 22.60M
June 30, 2022 28.03M
March 31, 2022 35.71M
December 31, 2021 43.99M
September 30, 2021 52.28M
June 30, 2021 63.24M
March 31, 2021 72.49M
December 31, 2020 27.34M
September 30, 2020 30.60M
June 30, 2020 34.51M
Date Value
March 31, 2020 39.50M
December 31, 2019 44.09M
September 30, 2019 47.88M
June 30, 2019 51.40M
March 31, 2019 55.61M
December 31, 2018 59.34M
September 30, 2018 0.6905M
June 30, 2018 4.144M
March 31, 2018 0.616M
December 31, 2017 3.658M
September 30, 2017 5.936M
June 30, 2017 8.566M
March 31, 2017 4.141M
December 31, 2016 6.185M
September 30, 2016 7.494M
June 30, 2016 -19.33M
March 31, 2016 -25.70M
December 31, 2015 -21.36M
September 30, 2015 -2.621M
June 30, 2015 -9.813M
March 31, 2015 -1.766M
December 31, 2014 -1.024M
September 30, 2014 -0.6562M
June 30, 2014 -2.563M
March 31, 2014 -5.506M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
Krystal Biotech, Inc. 1.359B
Tenaya Therapeutics, Inc. 69.41M
Ironwood Pharmaceuticals, Inc. -161.84M
Vericel Corp. 370.04M
SELLAS Life Sciences Group, Inc. 137.66M

Shareholders Equity (Quarterly) Related Metrics